ReviewInternational journal of molecular sciences2022
Probing Interleukin-6 in Stroke Pathology and Neural Stem Cell Transplantation.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- Different light color temperatures in the morning on the effectiveness of rehabilitation training in patients with ischemic stroke: a prospective, single-center, randomized controlled clinical trial.Journal of neuroengineering and rehabilitation · 2025Trial
- Astragalus-Safflower Combination Promotes Vascular Neogenesis in a Rat Model of Ischemic StrokeCurrent pharmaceutical design · 2026Article
- Early diagnosis of transient ischemic attack facilitated by SERS-based artificial intelligence sensors.Mikrochimica acta · 2025Article
- Targeting Ischemic Stroke with Neural Stem Cells: Insights into Endogenous Repair Mechanisms, Biomaterial-Based Delivery, and Exosome Therapies.Molecular neurobiology · 2025Review
- The Role of IL-6 in Ischemic Stroke.Biomolecules · 2025Review
- Article
- Association study of S100A9 gene polymorphisms with Parkinson's disease risk and age of disease onset.Acta neurologica Belgica · 2024Article
- Inflammatory marker profiles and in-hospital neurological deterioration in patients with acute minor ischemic stroke.CNS neuroscience & therapeutics · 2024Article
- Stem cell-based ischemic stroke therapy: Novel modifications and clinical challenges.Asian journal of pharmaceutical sciences · 2024Review
- Attenuation of amyotrophic lateral sclerosis via stem cell and extracellular vesicle therapy: An updated review.Neuroprotection (Chichester, England) · 2023Article
- Preconditioning Concepts for the Therapeutic Use of Extracellular Vesicles Against Stroke.Stem cells translational medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stem cell transplantation is historically understood as a powerful preclinical therapeutic following stroke models. Current clinical strategies including clot busting/retrieval are limited by their time windows (tissue plasminogen activator: 3-4 h) and inevitable reperfusion injuries. However, 24+ h post-stroke, stem cells reduce infarction size, improve neurobehavioral performance, and reduce inflammatory agents including interleukins. Typically, interleukin-6 (IL-6) is regarded as proinflammatory, and thus, preclinical studies often discuss it as beneficial for neurological recuperation when stem cells reduce IL-6's expression. However, some studies have also demonstrated neurological benefit with upregulation of IL-6 or preconditioning of stem cells with IL-6. This review specifically focuses on stem cells and IL-6, and their occasionally disparate, occasionally synergistic roles in the setting of ischemic cerebrovascular insults.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.